The ROE as of September 2024 (TTM) for BELLUS Health Inc. (BLU) is -13.91%

According to BELLUS Health Inc.’s latest financial reports and current stock price. The company's current ROE is -13.91%. This represents a change of 227.99% compared to the average of -4.24% of the last 4 quarters.

BELLUS Health Inc. (BLU) Historical ROE (quarterly & annually)

How has BLU ROE performed in the past?

The mean historical ROE of BELLUS Health Inc. over the last ten years is -17.47%. The current -13.91% ROE has changed -20.38% with respect to the historical average. Over the past ten years (40 quarters), BLU's ROE was at its highest in in the December 2015 quarter at 9.81%. The ROE was at its lowest in in the September 2021 quarter at -23.95%.

BELLUS Health Inc. (BLU) ROE by Quarter and Year

Discovering the peaks and valleys of BELLUS Health Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

BELLUS Health Inc. (BLU) Average ROE

How has BLU ROE performed in the past?

The current ROE of BELLUS Health Inc. (BLU) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

BELLUS Health Inc. (BLU) ROE vs. Peers

How is BLU’s ROE compared to its peers?

BELLUS Health Inc.’s ROE is greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Inozyme Pharma, Inc. (-68.93%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than KalVista Pharmaceuticals, Inc. (-97.37%), greater than Crinetics Pharmaceuticals, Inc. (-62.63%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Kura Oncology, Inc. (-40.43%), greater than Viridian Therapeutics, Inc. (-49.65%), less than Biomea Fusion, Inc. (0%), greater than Stoke Therapeutics, Inc. (-91.86%), greater than Akero Therapeutics, Inc. (-57.89%), greater than Homology Medicines, Inc. (-29.56%), greater than Gossamer Bio, Inc. (-100.91%), greater than Cytokinetics, Incorporated (-117.33%), less than DICE Therapeutics, Inc. (196.01%), greater than Edgewise Therapeutics, Inc. (-102.37%), greater than Karuna Therapeutics, Inc. (-28.01%), greater than Dyne Therapeutics, Inc. (-30.79%), greater than null (-68.85%),

Build a custom stock screener for BELLUS Health Inc. (BLU) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BELLUS Health Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BELLUS Health Inc. (BLU) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BELLUS Health Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.